cover image European Journal of Neurology

European Journal of Neurology

2025 - Volume 32
Issue 2 | February 2025

ISSUE INFORMATION

Issue Information

ORIGINAL ARTICLE

Background

The p.A53T variant in the gene was considered, until recently, to be the only variant causing familial Parkinson's disease (PD) in the Greek population. We identified a novel heterozygous p.A30G (c.89 C>G) pathogenic variant in five affected individuals of three Greek families, leading to autosomal dominant PD. This study aims to further explore the presence and phenotypic expression of this variant in the Greek PD population.

Methods

Restriction fragment length polymorphism (RFLPs) was used for genotyping of 664 Greek PD cases. Detailed clinical information was obtained for the carriers and p.A30G‐positive samples underwent haplotype analysis.

Results

We identified 10 additional p.A30G‐positive PD patients (1.5%), of whom 4 were sporadic cases (0.9%). They manifested typical Parkinsonian motor dysfunction, with a mean age of onset of 51.7 years (range: 33–62) and a broad spectrum of non‐motor symptoms. The absence of affected first degree relatives in four out of ten index cases, and the presence of a phenocopy in an additional family, suggest that the p.A30G variant manifests reduced penetrance. The common haplotype among the p.A30G carriers confirmed a founder effect. Furthermore, two asymptomatic carriers were identified, with possible premotor manifestations.

Conclusions

These findings underscore that the p.A30G pathogenic variant represents an important, albeit rare, cause of genetic PD in the Greek population. This is the first time in which a genetic synucleinopathy, with a variant in the gene, is clearly linked to an appreciable frequency of sporadic PD in a particular population.

ORIGINAL ARTICLE

Background and purpose

Up to 80% of patients diagnosed with reversible cerebral vasoconstriction syndrome (RCVS) experience complications such as ischaemic stroke, intracerebral or subarachnoid haemorrhage or posterior reversible encephalopathy syndrome. The aim was to evaluate the incidence of complications in patients diagnosed with RCVS in our clinic.

Patients and methods

All adult patients (age >16 years) diagnosed with RCVS at the Helsinki University Central Hospital during the period between 1 January 2016 and 31 December 2022 were retrospectively identified. Medical and follow‐up data were collected from medical records.

Results

Eighty patients diagnosed with RCVS were identified, of whom four patients had parenchymal lesions such as ischaemic stroke, intracerebral haemorrhage, posterior cerebral encephalopathy syndrome, subarachnoid haemorrhage or combinations thereof.

Conclusion

The complication rate of RCVS is lower than in previously published cohorts. This may be related to better and earlier diagnostics and earlier withdrawal of possible triggers.

ORIGINAL ARTICLE

Background

Epilepsy significantly impacts on morbidity and mortality. Understanding hospitalization and mortality risks in persons with epilepsy (PWE) is essential for improving healthcare strategies. We aimed to investigate the risk and causes of hospitalization and mortality in PWE compared to a matched general population cohort.

Methods

The EpiLink Bologna historical cohort study analyzed adult PWE in the period 2018–2019. A general population control cohort was used for comparison. Clinical data were linked with health administrative data. PWE were grouped into persons with focal epilepsy, idiopathic generalized epilepsy, and developmental and/or epileptic encephalopathy (PDEE). The primary outcome was the hospitalization rate. Emergency department (ED) visit rate and the risk of death for any cause were also assessed.

Results

The study included 1438 PWE and 14,096 controls. PWE had higher incidence rate ratio (IRR) for ED visit (IRR 1.26, 95% CI 1.20–1.32), hospital admission (IRR 2.05, 95% CI 1.83–2.29), and death (IRR 1.5, 95% CI 1.1–2.2) compared to control cohort. The highest hospitalization risk was in the PDEE group (IRR 4.70; 95% CI 3.28–6.74). The increased hospitalization rate among PWE was due to both their higher ED visit and elective hospital admission rates. PWE on polytherapy were at higher risk of hospitalization for inflammation of jaw, acid–base/electrolyte imbalances, chronic cerebrovascular disease, major traumas and infections.

Conclusions

During a 2‐year‐period, PWE in Bologna had a doubled risk of hospitalization and 50% higher risk of death compared to a matched general population cohort. Hospitalization risks varied significantly by epilepsy type and antiseizure therapy.

ORIGINAL ARTICLE

Background

The Italian Interceptor project is aimed at identifying a prodromal dementia phase and developing a nationwide organizational model. This study compares the sociodemographic and neuropsychological characteristics of mild cognitive impairment non‐converters (MCI‐NC) and MCI‐converters (MCI‐C) to dementia, including Alzheimer's disease (AD), enrolled during the Interceptor project.

Methods

Sociodemographic, clinical, and neuropsychological data of MCI individuals were collected at baseline (December 2018 to October 2020) and every six‐month follow‐up visit for 3 years. Logistic regression and Random Forest classifier were used to describe the study population.

Results

From 356 participants, 104 were MCI‐C, whereas 252 were MCI‐NC. Compared to MCI‐NC, MCI‐C were predominantly female ( = 0.020), older ( < 0.001), and more cognitively impaired ( < 0.001). Higher physical activity was protective for progression ( < 0.001), but no difference was observed for smoking exposure ( = 0.312) between the two groups. Similar results were found for AD individuals compared to MCI‐C/non‐AD. The ROC curve based on a Random Forest classifier distinguishing MCI‐C from MCI‐NC showed an area under the curve (AUC) of 0.7347.

Conclusions

Our findings confirm previous evidence in literature and may increase the insight on dementia pathology and help in defining intervention strategies to prevent or slow down disease progression.

ORIGINAL ARTICLE

Objective

Disorders of arousal (DoA) are characterized by an intermediate state between wakefulness and deep sleep, leading to incomplete awakenings from NREM sleep. Multimodal studies have shown subtle neurophysiologic alterations even during wakefulness in DoA. The aim of this study was to explore the brain functional connectivity in DoA and the metabolic profile of the anterior and posterior cingulate cortex, given its pivotal role in cognitive and emotional processing.

Methods

Fifteen consecutive patients with DoA (9 males, mean age 26.3 ± 7.7) and 15 age‐ and sex‐matched healthy controls (8 males, mean age 25.8 ± 3.6) were enrolled. All participants underwent a protocol including sleep and psychological evaluation scales and multimodal brain MRI with resting‐state functional MRI and 1H‐MR spectroscopy.

Results

The independent component analysis disclosed an altered resting‐state functional connectivity (FC) in the patients' sensory motor network, with a higher connectivity strength in opercular cortex, precuneus, occipital pole, and lingual gyrus. The seed‐based analysis revealed a decreased FC between posterior cingulate cortex (PCC) and several cerebral areas. Finally, spectroscopic imaging revealed a reduced content of glutamine in the PCC ( < 0.001).

Interpretation

The increased connectivity in the sensory‐motor network of DoA patients could constitute a “facilitatory medium” enhancing motor circuit activation, while the connectivity and metabolic alterations of PCC might represent a trait functional feature, contributing to a dysfunctional arousal process and the difficulty to reach a complete awareness during DoA episodes. In addition, these alterations at rest might be related to daytime impairment reported by patients, requiring new strategies for DoA management.

ORIGINAL ARTICLE

Background

Patients with post‐COVID condition (PCC) and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) experience symptoms potentially associated with small fiber neuropathy (SFN).

Methods

A sample of 90 participants, comprising 30 PCC patients, 30 ME/CFS patients, and 30 healthy controls (HC), matched by sex and age, was assessed. Neuropathic, autonomic, and fatigue symptoms were measured with TaskForce Monitor, the Sudoscan, heat and cold evoked potentials, In Vivo Corneal Confocal Microscopy (IVCCM), and specialized questionaries.

Results

PCC and ME/CFS patients demonstrated significantly higher levels of autonomic symptoms ( = 39.89,  < 0.001), neuropathic symptoms ( = 48.94,  < 0.001), and fatigue ( = 49.29,  < 0.001) compared to HC. Quantitative sensory testing revealed significant differences in heat detection thresholds between PCC patients and HC ( = 4.82;  < 0.01). Regarding corneal small fiber tortuosity, there were statistically significant differences between patients and HC ( = 6.80;  < 0.01), indicating pathological responses in patients. Small fiber tortuosity in IVCCM was identified as the main discriminator between patients and HC (AUC = 0.720;  < 0.01).

Conclusion

PCC and ME/CFS patients demonstrated sensory SFN, as evidenced by impaired heat detection and increased tortuosity of small fibers in the central corneal subbasal plexus. The findings underscore the importance of a multimodal approach to comprehensively detect and characterize SFN. This study provides valuable scientific insights into the neuropathic manifestations associated with these conditions.

ORIGINAL ARTICLE

Background

We investigated the relationship of piriform cortex (PC) structural network centrality with drug resistance and epilepsy duration as markers of sustained epileptic activity.

Methods

PCs were manually delineated on retrospectively collected 3D‐T1‐MRI images of patients with temporal lobe epilepsy (TLE). Connectomes were computed from diffusion MRI scans, including the PC as network nodes. Betweenness centrality (BC) and node degree were computed and compared across drug‐resistant versus drug‐sensitive patients. Correlations of centrality metrics with the duration of epilepsy were calculated.

Results

Sixty‐two patients (36 females, 43/62 drug‐resistant) were included in the main analysis. Greater centrality of the left PC was associated with drug resistance (degree:  = 0.00696,  = 0.85; :  = 0.00859,  = 0.59; alpha = 0.0125). Furthermore, left PC centrality was correlated with epilepsy duration (degree: rho = 0.39,  = 0.00181; : rho = 0.35,  = 0.0047; alpha = 0.0125). Results were robust to analysis of different parcellation schemes. Exploratory whole‐network analysis yielded the largest effects in the left PC. Finer parcellations showed stronger effects for both analyses in the left olfactory cortex rostral to PC. In 28 subjects who had received epilepsy surgery, a trend of smaller centrality in patients with ILAE I outcome was observed in this area.

Conclusions

We demonstrated an increased centrality of the left PC in patients with drug‐resistant TLE, which was also associated with the epilepsy duration. Recurring seizures over long periods may lead to changes of network properties of the PC. Large effects immediately rostral to our delineated PC region suggest a role of olfactory cortex anterior to the limen insulae in epileptogenic networks.

ORIGINAL ARTICLE

Background

Data on Escalation Therapy versus Early Intensive Therapy (EIT) Strategy in multiple sclerosis (MS) are lacking, particularly in Afro‐Caribbean cases, known for their severity.

Objectives

To assess efficacy and safety of these strategies in a predominantly Afro‐Caribbean relapsing–remitting MS population.

Methods

A multicenter retrospective study of 195 MS patients, including 66 on EIT, with ≥2 years follow‐up. Primary outcome: Kaplan–Meier curves and log‐rank test were used to assess irreversible progression to EDSS scores of 3, 6, and 8. Secondary outcomes: change in EDSS score, risk factors for EDSS progression, and severe adverse effects.

Results

EIT showed slower EDSS 3 progression than Escalation (median survival 13.5 vs. 9.8 years,  = 0.024). After a median follow‐up of 8 years, 89.5% on EIT remained free from EDSS 3 versus 63.8% on Escalation. Univariate analysis linked Escalation (hazard ratio (HR; 95% CI): 2.42 [1.09–5.34]), age at first relapse (HR: 1.04 [1.01–1.06]), incomplete symptom regression (HR: 1.69 [1.02–2.77]), and EDSS 3 progression. EDSS stabilized or decreased with EIT but worsened with Escalation ( < 0.001). Safety profiles were similar.

Conclusions

EIT extends median time to irreversible EDSS 3 in Afro‐Caribbean individuals compared to Escalation, supporting its preference as initial treatment.

ORIGINAL ARTICLE

Background and Objective

High‐efficacy (HE) disease‐modifying therapies (DMT) are increasingly used to treat multiple sclerosis (MS). Concerns arise when considering the decreasing efficacy and increasing risk of adverse events in aging patients. We aimed to describe disease activity and treatment trajectories in patients with MS who de‐escalated from an HE DMT to an moderate‐efficacy (ME) DMT.

Methods

We performed a cohort study based on data from the Danish Multiple Sclerosis Registry (DMSR) including patients with relapsing–remitting MS (RRMS), who switched from an HE DMT to an ME DMT as defined by Danish authorities. We included patients from October 2007 to July 2023. Median follow‐up time was 0.8 years (IQR 0.3–2.5).

Results

In total 333 patients (76.0% females, mean age: 45.1 years) de‐escalated for various reasons. Most patients de‐escalated from natalizumab or fingolimod (43.8% and 42.0%, respectively) to dimethyl fumarate (47.5%). At 2 years after de‐escalation, the cumulative risk of relapse was 38% (95% CI 31–44) and 53% (95% CI 46–60) for inflammatory disease activity (relapses and/or radiological disease activity). Age (HR 0.96, 95% CI 0.94–0.98) and inflammatory disease activity prior to de‐escalation (HR 2.05, 95% CI 1.45–2.91) were associated with inflammatory disease activity post de‐escalation.

Discussion

De‐escalation from primarily natalizumab and fingolimod did not effectively ensure disease stability in this cohort. Younger age and inflammatory disease activity prior to de‐escalation were risk factors for inflammatory disease activity post de‐escalation, which can help guide future studies on de‐escalation.

ORIGINAL ARTICLE

Background

To investigate the relevance of hyperperfusion on computerised perfusion imaging (CTP) in the emergency setting in people with non‐convulsive status epilepticus (NCSE) and previous stroke, to derive relevant aspects on the epileptogenic focus and the network recruited for NCSE propagation.

Methods

We enrolled consecutive adult patients with acute‐onset NCSE and a previous stroke at a single institution undergoing CTP and EEG during symptoms. All patients underwent standard imaging including CT, CTP, CT angiograms and standard EEG within 30 min from hospital arrival. Age‐/sex‐matched NCSE without previous stroke cases and recurrent ischaemic stroke cases were included to test for accuracy of hyperperfusion rates.

Results

Overall, 15 patients had a previous stroke and developed NCSE (mean age 78 years, 46.7% female). All patients had hyperperfusion on CTP imaging (mean onset‐to‐CTP 184 min). Only one case showed hyperperfusion limited to the previous stroke lesion, and one had a combination of lesional and peri‐lesional hyperperfusion. All remaining cases ( = 13) had exclusive extra‐lesional involvement. Five cases had multiple separated hyperperfused areas, and five had ipsilateral intra‐thalamic hyperperfusion. No correlation emerged between onset‐to‐CTP timing and hyperperfusion ( value for CTP = 0.66, CBV = 0.28, MTT = 0.28, reverse  = 0.66). Hyperperfusion was present in NCSE cases only and in none of age‐/sex‐matched ischaemic stroke cases ( = 18).

Conclusions

Hyperperfusion involves cortical areas external to the previous lesion site during NCSE, supporting the relevance of networks for the spatial evolution of epileptic activity and limited relevance of the lesion site for the propagation of the epileptiform activity.

ORIGINAL ARTICLE

Background and Purpose

This study aims to assess the disease burden and care quality along with cross‐country inequalities for stroke at global, regional, and national levels from 1990 to 2021.

Methods

Data on stroke were extracted from the Global Burden of Disease (GBD) study 2021 for the globe, five sociodemographic index (SDI) regions, 21 GBD regions, and 204 countries/territories. The disease burden was quantified using the age‐standardized disability‐adjusted life years rate (ASDR). Quality of care (QoC) was evaluated through the age‐standardized QoC index (QCI). To assess cross‐country disparities in both disease burden and age‐standardized QCI, the slope index of inequality (SII) and the concentration index were utilized.

Results

From 1990 to 2021, the global ASDR of stroke decreased from 3078.95 (95% uncertainty interval [UI]: 2893.58, 3237.34) to 1886.20 (95% UI: 1738.99, 2017.90) per 100,000 population, while the age‐standardized QCI improved from 50.79 to 64.61. However, the results of inequalities showed worsening inequalities in both ASDR and QCI, with lower SDI countries shouldering a disproportionate burden and higher SDI countries maintaining higher QoC. The SII and concentration index for ASDR indicated a worsening inequality among lower SDI countries, with SII increasing to −2616.44 and the concentration index increasing to −0.1119 in 2021. Meanwhile, the SII and concentration index for age‐standardized QCI showed a worsening inequality among higher SDI countries, with SII of 27.48 and concentration index of 0.0922 in 2021.

Conclusions

Despite notable global advancements, significant disparities in stroke still exist, particularly in lower SDI regions facing high disease burdens and substandard care.

ORIGINAL ARTICLE

Background

Headache is the most common presenting symptom of intracranial hypotension (IH), and it usually has orthostatic features. However, the outcome of IH and the persistence and characteristics of headache are still overlooked.

Methods

In this cohort study, patients diagnosed with IH in our institute between 2018 and 2024 were included. Demographical and clinical data, headache characteristics, etiology, type of treatment (epidural blood patch (EBP), surgical or conservative), and MRI findings were collected. We conducted follow‐up visits on headache characteristics and the persistence of headache ≥ 12 months of EBP/conservative treatment.

Results

Forty‐five patients with a diagnosis of IH were included (mean age of 53.0 ± 14.9 years); 35 (77.8%) were diagnosed with spontaneous intracranial hypotension (SIH) and 10 (22.2%) with secondary IH. EBP was performed on 22 patients (48.9%). Headache was the most common symptom at presentation, in 38/45 patients (84.4%), with orthostatic features in 32 (71.1%). Forty‐four patients (97.8%) had brain MRI abnormalities. Follow‐up visits were conducted after 31.6 ± 15.7 months; 28/41 (68.3%) patients reported headache during the first 12 months, and 22/41 (53.7%) ≥ 12 months. Headache persistence for ≥ 12 months was significantly lower in patients who received EBP (27.3%) compared to those who did not (63.2%) ( = 0.021). Logistic regression showed that receiving EBP was the only factor significantly associated with reduced likelihood of persistent headache for ≥ 12 months (OR = 0.082, 95% CI [0.007,0.903],  = 0.041). Radiological features differed significantly between patients with SIH and those with secondary etiologies.

Conclusion

A large proportion of patients with IH continue to experience headache beyond one year; EBP was the only predictor of headache persisting ≥ 12 months.

ORIGINAL ARTICLE

Background

Relapsing–remitting (RR) and primary progressive (PP) multiple sclerosis (MS) have distinct clinical courses, but underlying pathophysiological differences remain unclear. We compared pathological components between RRMS, PPMS, and other inflammatory and neurodegenerative disorders, leveraging soluble biomarkers and post‐mortem pathology.

Methods

Serum and cerebrospinal fluid (CSF) of people diagnosed with (pw) PPMS ( = 104), RRMS ( = 38), Alzheimer's disease (AD,  = 22), neuromyelitis optica spectrum disorder (NMOSD,  = 10), and myelin oligodendrocyte glycoprotein–associated disease (MOGAD,  = 10) were collected. B‐cell maturation antigen (BCMA), soluble CD27 (sCD27), osteopontin (OPN), chitinase‐3‐like‐1 (CHI3L1), glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL) and synaptosomal‐associated protein‐25 (SNAP25) were measured. Lymphocytes (CD20, CD138, CD3) and pyramidal‐tract axonal density in RR‐onset ( = 86) and PPMS ( = 45) post‐mortem brain tissue were quantified.

Results

Soluble and post‐mortem tissue biomarkers did not differ between pwRRMS and pwPPMS. Compared to AD, MS had higher CSF sCD27 ( < 0.001) but lower serum CHI3L1 and GFAP, and CSF OPN and SNAP25 (all  < 0.05). Serum OPN was lower in RRMS than NMOSD ( = 0.013). Principal component analyses and K‐means clustering showed substantial overlap of RRMS and PPMS biomarkers, distinct from AD. In all pwMS, serum NfL and CSF BCMA correlated with clinical/radiological disease activity, CSF BCMA and sCD27 with inflammatory parameters, and serum GFAP, CSF GFAP, and CSF NfL with Expanded Disability Status Scale (EDSS) score.

Conclusions

Serum and CSF soluble biomarker profiles and post‐mortem pathology do not differentiate RRMS from PPMS diagnoses but reflect the extent of inflammation and tissue damage. Detailed assessment of MS‐associated inflammation and tissue damage may enhance classification and therapeutic strategies.

ORIGINAL ARTICLE

Background

Short‐lasting paroxysms of facial pain in patients with cluster headache have traditionally been called “cluster tics.” Mostly described as co‐occurring trigeminal neuralgia, they remain to be explored as an independent phenomenon. We investigated the prevalence of cluster tics in cluster headache, the clinical differentiation from trigeminal neuralgia, and propose a distinct definition and renaming of cluster tics.

Methods

We conducted a retrospective, controlled, cross‐sectional study using semi‐structured interviews of patients with cluster headache at the Danish Headache Center. A comparator cohort of patients with trigeminal neuralgia was included from a previous study. We investigated the lifetime prevalence of cluster tics in the cluster headache group and characterized them according to duration, location, pain‐intensity, triggerability, and serial occurrence.

Results

We included 424 participants with cluster headache (median age 52 years (IQR: 32–72), male–female ratio 3:2) and 576 participants with trigeminal neuralgia (median age 72 years (IQR: 50–94), male–female ratio 1:3). Cluster tics were reported by 200 (47%) cluster headache participants with higher odds for participants of female sex (OR: 1.94, 95% CI: 1.27–2.96,  0.002) and participants with chronic cluster headache (OR: 1.74, 95% CI: 1.15–2.63,  0.008). Unlike trigeminal neuralgia, cluster tics were not triggerable (OR: 0.02, 95% CI: 0.01–0.04,  < 2e‐16) and presented with pain restricted to the first trigeminal division.

Conclusions

Cluster tics are prevalent in nearly half of patients with cluster headache, associated to female sex and chronic phenotype. Unlike trigeminal neuralgia, cluster tics occur in the orbital region and are largely non‐triggerable. To improve terminology, we propose renaming cluster tics to “cluster stabs.”

ORIGINAL ARTICLE

Background

The cortico‐striato‐thalamo‐cortical circuits play a crucial role in the pathogenesis of Tourette syndrome (TS). While iron deficiency has been reported in adult TS, the iron content in pediatric TS remains poorly understood. This study aims to quantitatively assess whole‐brain iron deposition in pediatric TS compared to typically developing (TD) children using quantitative susceptibility mapping (QSM).

Methods

In this prospective study, we recruited 50 children with a clinical diagnosis of TS and 50 age‐ and gender‐matched TD controls. Whole‐brain images were acquired using 3D T1 and multi‐echo gradient‐recalled echo sequences. QSM maps were generated using the STISuite toolbox. After normalizing the QSM maps to Montreal Neurological Institute space, voxel‐based analysis was applied to compare between‐group differences in iron content. Additionally, we evaluated the relationship between iron content and tic severity in TS children using the Pearson's correlation test.

Results

Compared to TD children, those with TS exhibited iron deficiency in the right anterior cingulum ( < 0.001). Conversely, increased QSM values were observed in the bilateral putamen of TS children ( < 0.001). Notably, QSM values in the left putamen showed a significant negative correlation with tic severity ( = 0.044).

Conclusions

Our findings suggest that disturbed brain iron homeostasis in specific regions is associated with pediatric TS. These results reinforce the importance of the cortico‐striato‐thalamo‐cortical circuits in TS pathogenesis and highlight the potential role of iron dysregulation. Furthermore, our study demonstrates that QSM could serve as a valuable auxiliary biomarker for diagnosing and potentially monitoring pediatric TS.

ORIGINAL ARTICLE

Background

Amyotrophic lateral sclerosis (ALS) is characterized by the degeneration of both upper and lower motor neurons (UMNs and LMNs). Recognizing the involvement of UMNs is challenging because of the absence of reliable biomarkers beyond clinical evaluation.

Aim

To identify a reliable marker of UMN damage in a cohort of patients with ALS referring to the Motor Neuron Disease Clinic of the University Hospital of Padova.

Methods

We retrospectively evaluated the clinical records of 79 patients with ALS and compared the results of various investigations, including the motor‐evoked potentials (MEPs), positron emission tomography–magnetic resonance imaging (MRI) and light neurofilaments (NfLs), with the degree of UMN clinical involvement, as assessed by the Penn Upper Motor Neuron Score (PUMNS).

Results

MEPs, considering the central motor conduction time (CMCT) values in both the upper and lower limbs, showed a significant correlation with the relative PUMNS subscores ( = 0.01,  = 0.4; and  = 0.005,  = 0.45, respectively). Additionally, there was a positive correlation between NfLs and PUMNS values ( = 0.04,  = 0.33). The presence of the motor band sign on MRI was associated with higher PUMNS values. Receiver operating characteristic analysis revealed that PUMNS accurately predicted abnormalities in CMCT values (specificity 86%, sensitivity 62%) and the presence of the motor band sign (specificity 58%, sensitivity 80%).

Interpretation

In our cohort of patients with ALS, CMCT values proved to be the most reliable test for assessing UMN involvement, albeit the presence of the motor band sign on MRI showed higher sensitivity.

ORIGINAL ARTICLE

Background

Hereditary transthyretin (ATTRv) amyloidosis is a rare, adult‐onset autosomal‐dominant disorder caused by pathogenic variants in the transthyretin () gene. Data about relevant variants in specific populations and typical initial manifestations may facilitate early diagnosis and treatment. We here describe the genetic landscape of ATTRv amyloidosis in Israel.

Methods

Genetic and clinical data of variant carriers and ATTRv amyloidosis patients were collected from a national referral clinic and other subspecialty clinics in Israel. Genotype–phenotype correlations of the detected variants were detailed. In addition, two large Israeli exome sequence (ES) databases were screened for variants.

Results

Seven heterozygous disease‐causing variants in were identified among 95 adults (52 males, 50.7%). The Ser77Tyr variant was found in 68 (71.6%) subjects of Jewish Yemenite ancestry. Val122Ile was found in 9 (9.4%) subjects and was the only variant detected in individuals of Arab ethnicity. Other variants were Thr60Ala, Val30Met, Val32Ala, Ala81Val, and Glu89Val. Thirty‐five individuals were ATTRv amyloidosis patients (25 males, 71.4%), diagnosed at a mean age of 62.5 ± 6.7 years, and 23 (63.7%) were due to Ser77Tyr. Initial symptoms were mostly related to carpal tunnel syndrome, and the sensitivity of scintigraphy was low for Ser77Tyr but high for Thr60Ala and Val32Ala variants. pathogenic variants were detected in 14 of approximately 36,600 subjects who underwent ES, including Val122Ile in 9 subjects of Arab ethnicity.

Conclusions

Most ATTRv amyloidosis cases in Israel are attributable to the Ser77Tyr variant. However, other variants also contribute to disease occurrence, and testing is warranted in clinically suspected patients.

ORIGINAL ARTICLE

Background

Smoking and obesity interact to exacerbate the risk of hypertension, diabetes, and cardiovascular disease, but their potential synergistic effects on outcomes in multiple sclerosis (MS) have not been well studied. We aimed to study whether smoking and obesity interact to affect disease progression and cognitive function in patients with MS.

Methods

Incident cases from the population‐based case–control study Epidemiological Investigation of MS (EIMS) were categorized by smoking and obesity status at diagnosis and followed up to 15 years postdiagnosis through the Swedish MS registry ( = 3336). Cox regression was used to analyze outcomes, including clinical disease worsening (CDW), progression to Expanded Disability Status Scale (EDSS) levels 3 and 4, physical worsening as measured by a 7.5‐point increase in the MS Impact Scale (MSIS) physical score, and cognitive decline, defined as an 8‐point or greater reduction on the Symbol Digit Modalities Test (SDMT). Interaction effects on the additive scale were assessed by combining dichotomous variables for smoking (nonsmoker = 0, smoker = 1) and obesity (nonobese = 0, obese = 1), yielding four categories: 0/0 (reference category), 0/1, 1/0, and 1/1.

Results

Additive interactions between smoking and obesity were identified for CDW (attributable proportion due to interaction [AP] 0.18, 95% CI 0.03–0.30), progression to EDSS 4 (AP 0.18, 95% CI 0.08–0.26), MSIS‐Physical score worsening (AP 0.32, 95% CI 0.21–0.42), and cognitive decline (AP 0.27, 95% CI 0.19–0.35).

Conclusions

Smoking and obesity appear to synergistically worsen MS progression and cognitive functioning, with the observed additive interactions across most outcomes suggesting that these factors partly share common biological pathways contributing to disease progression.

LETTER TO THE EDITOR

Reassessing the Role of the Neurofilament Light Chain in Guillain‐Barre Syndrome: Issues in Diagnosis and Subgroup Classification

ORIGINAL ARTICLE

Background

Diabetes is an established risk factor for dementia. However, the association has been less consistent at the population level and may vary over the lifespan. The impacts may be influenced by glucose fluctuation over lifetime.

Methods

We used data from the Framingham Offspring cohort to evaluate the dementia risk associated with fasting blood glucose (FBG) across age ranges. Cox proportional hazards regression models were fitted to investigate the association of diabetes status at each examination with dementia risk, and the associations between FBG levels and dementia across age spans. Group‐based trajectory models were used to create FBG trajectories from mid to late‐life for comparison.

Results

Higher FBG level at midlife was not associated with an increased risk of dementia. For participants with diabetes, higher FBG at age 60 and 70 years was associated with subsequent dementia (HR: 1.72, 95% CI: 1.07–2.75; HR: 1.91, 95% CI: 1.24–2.91). Diabetic participants with first midlife increasing and then late‐life declining patterns of FBG were at greater increased risk of dementia compared to participant without diabetes. (HR: 2.00, 95% CI: 1.04–3.85).

Conclusion

The relationship between FBG and dementia risk was heterogeneous across the adult age range. Diabetes at midlife is a risk factor for dementia, but high glucose levels at 60–70 years followed by a decline suggests that less controlled diabetes during high age risk for dementia onset may represent another prodromal risk factor and presymptomatic metabolic indicator of dementia.

ORIGINAL ARTICLE

Background

Biallelic variants in polyribonucleotide‐nucleotidyltransferase‐1 (PNPT1) have been associated with a range of phenotypes from syndromic hearing loss to Leigh's syndrome. More recently, heterozygous variants in , have been reported in three families with cerebellar ataxia and prominent sensory neuropathy.

Methods

Whole genome sequencing was performed in two families with autosomal dominant sensory ataxic neuropathy (SAN).

Results

Segregating heterozygous splice site (c.2014‐3C>G) and nonsense (p.Arg715Ter) variants were detected in both families. All patients initially presented with an isolated SAN clinically and neurophysiologically with subsequent variable cerebellar involvement.

Conclusion

We report two heterozygous variants in two families with a predominant SAN, including the novel p.Arg715Ter. This strengthens the argument of causing dominant disease and highlights a new cause for dominantly inherited SAN.

LETTER TO THE EDITOR

Epilepsy Management in Transgender Population: More Research for Better Treatment

ORIGINAL ARTICLE

Background

Blood‐based biomarkers may offer a non‐invasive approach to diagnose cerebral amyloid angiopathy (CAA), especially in early‐stage. We evaluated the ability of plasma phosphorylated tau‐217 (p‐tau 217) to differentiate CAA from Alzheimer's disease (AD) and deep perforator arteriopathy (DPA).

Methods

Patients with AD (age 73.7 ± 8.1 years), probable CAA (74.8 ± 6.9 years), or DPA (66.1 ± 10.4 years) were enrolled from memory and stroke clinics at a medical center in Taiwan. All participants received amyloid and tau PET scans. Plasma biomarkers were measured via a SIMOA immunoassay platform. The diagnostic utility of p‐tau 217 was assessed using ROC analyses and the Youden cutoff. Associations between plasma p‐tau 217 and neuroimaging variables in CAA were explored.

Results

Patients with CAA had lower plasma p‐tau 217 (0.69 ± 0.76 vs. 1.28 ± 0.97 pg/mL,  < 0.001) and a lower p‐tau 217/Aβ40 ratio (0.003 ± 0.002 vs. 0.006 ± 0.003,  < 0.001) than the AD group but higher levels than the DPA group (p‐tau 217, 0.27 ± 0.13 pg/mL,  = 0.001; p‐tau 217/Aβ40, 0.001 ± 0.0005,  < 0.001), although adjustment attenuated the difference in p‐tau 217 between CAA and DPA. Plasma Aβ40, Aβ42, and Aβ40/Aβ42 were not significantly different between groups. Plasma p‐tau 217 had moderate to good diagnostic utility to differentiate CAA vs. AD (sensitivity, 64.4%; specificity, 89.5%; AUC, 0.809) and CAA vs. DPA (sensitivity, 67.8%; specificity, 100%; AUC, 0.855). In CAA, p‐tau 217 significantly correlated with the severity of CAA, amyloid PET signal intensity, and lobar microbleed count ( < 0.001).

Conclusions

Plasma p‐tau 217 may represent a non‐invasive biomarker for distinguishing cerebral amyloid angiopathy (CAA) from other conditions, including AD and DPA.

SHORT COMMUNICATION

Introduction

Patients diagnosed with optic neuritis (ON) who did not fulfil the diagnostic criteria for multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMO‐SD), tested negative myelin oligodendrocyte glycoprotein immunoglobulin G and for which a systemic disease has been excluded are classified as having idiopathic ON (IDON).

Methods

This was a monocentric retrospective observational study. Inclusion criteria were as follows: patients with IDON, absence of an alternative diagnosis during the first 2 years, follow‐up of at least 5 years.

Results

Thirty‐six patients were included. After a median follow‐up of 9 years, a diagnosis of IDON was retained for 77.8% ( = 28) of patients, whereas 22.2% ( = 8) converted to an alternative diagnosis after a median of 6 years. Four patients converted to MS, two to clinically isolated syndrome and two to seronegative NMO‐SD. Among the 28 patients who remained diagnosed with IDON, 42.9% ( = 12) experienced recurrent ON, occurring mostly (90%) within the first 5 years of the disease. Maintenance therapy was initiated in 10 of the 12 patients, among whom 6 patients had no recurrence under treatment. For the 28 patients who remained with IDON, the final best corrected visual acuity (BCVA) was variable. Respectively, 35.7% and 25.9% of patients had a BCVA inferior to 0.5 and 0.2, whereas 50% recovered a final BCVA of 10/10.

Conclusion

A significant proportion of the cohort converted to an alternative diagnosis after 2 years, encouraging an extended follow‐up of IDON patients. Maintenance therapies were often effective in case of recurrent ON.

ORIGINAL ARTICLE

Introduction

Second‐generation tau‐PET tracers like [F]MK‐6240 are increasingly used both for diagnosing and quantifying Alzheimer's Disease (AD) tauopathy. However, while [F]MK‐6240 tau‐PET has demonstrated excellent sensitivity for AD tauopathy, data assessing its specificity and binding in non‐AD tauopathies are still scarce.

Methods

Participants were assigned to exclusive categorical diagnoses based on their amyloid (Aβ) and cognitive status. We quantified mesiotemporal (MTL) and neocortical [F]MK‐6240 tau‐PET signal in 28 Aβ− cognitively impaired (CI) patients presenting various non‐AD neurodegenerative disorders. Tau‐PET quantifications were compared with Aβ− cognitively unimpaired (CU) subjects ( = 51) and Aβ+ CI patients ( = 77).

Results

Among the 28 Aβ− impaired subjects, only five presented significant and isolated mesiotemporal signal, most of them being suspected of primary age‐related tauopathy (PART). Only two Aβ− impaired patients (7%) presented positive neocortical signal, both being diagnosed with fronto‐temporal degeneration (FTD). The Tau‐PET results of all the remaining Aβ− patients were comparable to the CU population, including eight other FTD patients. Importantly, 4R‐only tauopathies (CBD and PSP) and sv‐PPA were negative.

Conclusion

[F]MK‐6240 tau‐PET has a special affinity for tauopathies involving 3R/4R paired helical filaments: AD, PART (Aβ− subjects with MTL‐restricted tau‐PET signal) and some forms of FTD while most primary tauopathies do not exhibit significant cortical signal. Positive neocortical scans are therefore highly specific for AD tauopathy. Based on those and previous results, we propose a diagnostic flowchart for MCI subjects suspected of AD or another tauopathy which may significantly reduce the need for amyloid PET or CSF measurement.

LETTER TO THE EDITOR

Reply to “Letter to the Editor: Pitfalls in Calculating the Incidence of GBS During the Pandemic”

EDITORIAL

Tirofiban Benefits the Outcome of Stroke Patients With Large Artery Atherosclerosis Achieving Full Reperfusion and High NIHSS Scores

LETTER TO THE EDITOR

Pitfalls in Calculating the Incidence of Guillain‐Barre Syndrome During the Pandemic

LETTER TO THE EDITOR

Response to Letter to the Editor: Clarifying Diagnostic Criteria and the Role of Serum Neurofilament Light Chain in Immune‐Mediated Neuropathies

EDITORIAL

Bridging the Gaps: Addressing Inequities in Neurological Care for Underserved Populations

ORIGINAL ARTICLE

Background

The Three‐Objects‐Three‐Places (3O3P) test is a 5‐min screen for episodic memory impairment due to Alzheimer's disease, known for its briefness and easy administration, culture‐ and language‐free nature, and the absence of specific equipment. However, no studies have validated its potential in memory clinic cohorts. The aim of this study was to test its convergent, discriminant, and known‐group validities and to define thresholds for its clinical use.

Methods

We included 2062 cognitively unimpaired (CU), mild cognitive impairment (MCI) and dementia patients from the Geneva Memory Center cohort who underwent the 3O3P test in the context of clinical practice. Convergent and discriminant validities were assessed using an exploratory factor analysis. The known‐group validity was assessed in CU vs. MCI and dementia using the area under the curve (AUC). 3O3P test scores vs. amyloid and tau positivity, neurodegeneration, and cognition (ATNC) were assessed using the Kruskal‐Wallis test. The 3O3P test cut‐offs were calculated using sensitivity, specificity, PPV, NPV, and accuracy.

Results

Mean age was 72 years (SD = 11), 60% were female, mean education was 13 years (SD = 4), and mean MMSE was 25 (SD = 5). The 3O3P and Delayed Total Recall tests loaded strongly on the “memory” factor and weakly on “non‐memory” factors. The 3O3P test can discriminate CU vs. MCI (AUC = 0.71) and dementia (AUC = 0.92). Higher 3O3P scores were associated with lower prevalence of ATNC ( < 0.001). A 3O3P value of 7 can detect MCI and dementia patients.

Conclusions

The 3O3P test has demonstrated good convergent, discriminant, and known‐group validity in a large memory clinic population.

SHORT COMMUNICATION

Background

Parkinson's disease is a progressive neurodegenerative disorder with no cure. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) may have neuroprotective effects. However, long‐term real‐world studies are needed to clarify their potential impact on Parkinson's disease.

Methods

This nationwide cohort study included 33,462 patients (16,731 GLP‐1RA initiators and 16,731 propensity score‐matched dipeptidyl peptidase‐4 inhibitor [DPP‐4i] initiators) from 2007 to 2018, followed until 2022. Eligible participants were ≥ 50 years, had no prior cancer or Parkinson's disease, and were residents in Denmark for at least 10 years. Patients were followed until Parkinson's diagnosis, death, emigration, treatment discontinuation (no additional prescription within 180 days), switch to the other study drug, or end of follow‐up. Additional analyses included comparisons with insulin, competing risk of death, and the main analysis disregarding adherence.

Results

During follow‐up, 192 patients developed Parkinson's disease, including 93 during sustained treatment. After 10 years, sustained GLP‐1RA users had a lower hazard ratio (HR 0.57 (95% CI 0.37;0.85)) and absolute risk difference (−0.24 (95% CI −0.63 to 0.15)) compared to DPP‐4i users. Similar trends were found when using insulin as a comparator. A significant survival advantage was found among sustained users of GLP‐1RA (particularly when comparing with insulin). When not accounting for adherence, the results was not statistically significant.

Conclusions

Results were suggestive for a potential neuroprotective effect of GLP‐1RAs against Parkinson's disease. Further studies are needed to assess biomarkers of disease progression, and evaluate safety in patients with Parkinson's disease, dosing, and effects when combined with other treatments in neurodegenerative diseases.

ORIGINAL ARTICLE

Introduction

Alzheimer's disease (AD) is a neurodegenerative condition characterised by amyloid plaque accumulation and neurofibrillary tangles. Early detection is essential for effective intervention, but current diagnostic methods that enable early diagnosis in clinical practice rely on invasive or costly biomarker scanning. This study aimed to explore the utility of 7T MRI in assessing hippocampal subfield volumes and their correlation with cerebrospinal fluid (CSF) biomarkers in prodromal AD.

Methods

Fifty‐six participants, including AD patients and healthy controls, underwent 7T MRI scanning. Automated segmentation delineated hippocampal subfield volumes, with subsequent normalisation to whole brain volume.

Results

Significant differences in hippocampal and subfield volumes were observed in prodromal AD patients, even when they did not exhibit high MTA scores on 3T MRI or show any whole brain volume loss. Additionally, the volume of the entorhinal cortex (ERC) correlated significantly with CSF amyloid‐β levels, suggesting ERC's potential as a proxy CSF amyloid‐ß measurement. Conversely, no significant associations were found between CSF 181‐Phosphorylated‐tau or total tau levels and any hippocampal subfield volumes.

Discussion

These findings show the potential use of 7T MRI, particularly in ERC assessment, as a biomarker for early AD identification. Further validation studies are warranted to confirm these results and elucidate the relationship of ERC volume with CSF biomarkers.

REVIEW ARTICLE

Background

Parkinson's disease (PD) treatments, such as apomorphine (APO) and levodopa–carbidopa intestinal gel (LCIG), represent advanced therapeutic options for managing motor symptoms. However, clear selection criteria and well‐defined cognitive outcomes are lacking. This systematic review specifically aimed to address these gaps by assessing the cognitive impact of APO and LCIG in PD patients.

Methods

A systematic review was conducted following PRISMA guidelines, with searches in PubMed, Web of Science, Scopus, and Embase. Two authors screened studies based on key inclusion criteria, including at least two cognitive tests, and a follow‐up of 6 months or more. The risk of bias was evaluated using the Newcastle–Ottawa Scale (NOS).

Results

Fifteen studies were identified (7 APO and 8 LCIG). APO generally preserved cognitive function over a 12‐month follow‐up, with some decreases in visuospatial memory and executive functions. LCIG, with a 28‐month follow‐up, showed more extensive cognitive decline, particularly in patients with pre‐existing impairments. Variability in cognitive tests made direct comparisons difficult.

Discussion

APO may have a more favorable cognitive profile than LCIG. However, differences in follow‐up duration, moderate risk of bias, and inconsistent cognitive assessments warrant cautious interpretation. Improved patient selection and comprehensive cognitive evaluations are recommended for future practice.

OBITUARY

Giancarlo COMI (1947–2024)

ORIGINAL ARTICLE

Objective

This study aimed to explore the associations between inflammatory markers and the severity of early neurological dysfunction and prognosis in patients with progressive stroke (PS) and evaluated the predictive value of inflammatory markers for PS.

Methods

Among 711 acute ischemic stroke (AIS) patients, 210 patients with PS and 501 patients without PS were included. Six inflammatory markers, including neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR), systemic immune‐inflammation index (SII), systemic inflammatory response index (SIRI), and pan‐immune‐inflammation value (PIV), were measured and compared between two groups. Correlation analysis was used to analyze the correlation between inflammatory markers and early neurological dysfunction in patients with PS. Univariate and multivariate regression analyses were applied to screen the factors for the prognosis of PS patients. The receiver operating characteristic (ROC) curve was utilized to evaluate the predictive value for the prognosis of PS patients.

Results

Elevated levels of NLR, LMR, SII, and PIV were observed in PS patients. Correlation analysis revealed positive correlations between NLR, PLR, SII, SIRI, PIV, and early neurological deficits, while LMR showed a negative correlation in PS patients. Multivariate analysis identified LMR and the National Institutes of Health Stroke Score (NIHSS) as independent risk factors for poor outcome of PS patients. The predictive value of LMR alone was limited (AUC = 0.59), but combining it with NIHSS improved predictive accuracy (AUC = 0.73) ( < 0.05).

Conclusion

These findings suggest that inflammatory markers, particularly LMR, should be considered in PS management, and their combination with NIHSS enhances outcome prediction.

ORIGINAL ARTICLE

Background

Axonal neuropathies are disorders that impair neural transmission, leading to substantial sensory deficits. In the auditory system, axonal degeneration can disrupt auditory processing, causing significant hearing difficulties. Understanding the extent of axonal degeneration and its impact on auditory function is crucial for improving diagnosis and management. This study aims to quantify axonal degeneration in the VIIIth nerve using diffusion‐weighted MRI and to correlate these findings with auditory function.

Methods

Fifty‐two children and adults participated. A total of, 27 with normal hearing, 7 with cochlear hearing loss and 18 with auditory neuropathy (AN). Hearing thresholds and dMRI data was collected for all participants and the VIIIth nerve was evaluated using the fixel‐based analysis metric of Apparent Fibre Density (AFD).

Results

AFD was significantly lower in participants with AN compared to participants with normal hearing and cochlear hearing loss ( < 0.05). 9/18 participants with AN exhibited AFD values ≥ 2 standard deviations below the normal range. Additionally, AFD was strongly correlated with hearing thresholds in participants with no evidence of cochlear dysfunction ( = −0.776,  < 0.001), suggesting reduced auditory nerve fibre density is associated with impaired sound detection.

Conclusions

dMRI‐derived AFD is a sensitive marker for axonal degeneration in the VIIIth nerve. This study provides the first in vivo evidence linking VIIIth nerve microstructure with hearing thresholds, highlighting the potential of dMRI in diagnosing and monitoring AN. The findings suggest that dMRI could be a valuable tool in clinical settings for assessing auditory nerve health and guiding treatment strategies for individuals with AN.

SHORT COMMUNICATION

Background and Aims

In 2019, we conducted a cross‐sectional study, collecting information on 50 patients with CMT4B, an ultrarare CMT subtype, to better define the clinical phenotype. We now aimed at investigating disease progression in 26 patients with CMT4B1/CMT4B2, recruited from the previous study and among the Inherited Neuropathy Consortium.

Materials and Methods

We retrospectively analysed disease progression in patients with CMT4B1/CMT4B2, collecting MRC scores from nine muscle pairs, Charcot‐Marie‐Tooth Examination Score (CMTES), and a minimal dataset of clinical information (walking difficulties, aids dependency, upper limb impairment, cranial nerves involvement) at baseline and follow‐up visits. Thirteen centres from four continents were involved.

Results

Thirteen CMT4B1 and 13 CMT4B2 patients were followed up for 7.1 ± 4.9 and 7.9 ± 4.5 years, respectively. During follow‐up, walking aid dependency increased: two CMT4B1 patients adopted AFOs (overall 11/12 at follow‐up), and one started using wheelchair (6/12 at follow‐up) at the age of 19; among CMT4B2 patients, two more required unilateral support in walking (4/11 at follow‐up) by the age of 33 and 49 years, respectively. We found that disease progression, as measured by CMTES, was faster in CMT4B1 as compared to CMT4B2 patients (ΔCMTES/year 0.7 vs. 0.3,  = 0.037) but tended to slow down over time as burden of disease increased. At the end of follow‐up, CMT4B1 was associated to higher disability.

Conclusions

This international collective effort enabled collection of relevant data for characterizing natural history and estimating disease progression of CMT4B1/CMT4B2 ultrarare diseases, aiming at improving their management and paving the way for designing future clinical trials.

ORIGINAL ARTICLE

Background

Autosomal dominant polycystic kidney disease (ADPKD) is frequently complicated by intracranial aneurysms (IAs). However, the genetic factors driving the elevated IA risk in ADPKD remain poorly understood. In this study, we identified a novel mutation associated with a remarkably high IA incidence in a large Chinese ADPKD family.

Methods

We conducted whole‐exome sequencing in a three‐generation Chinese ADPKD family ( = 24) characterized by an unusually high IA prevalence. The pathogenicity of the identified variant was validated through comprehensive functional studies, including protein localization, calcium signaling, and endothelial cell behavior analyses.

Results

We discovered a novel mutation (c.G10086T) that co‐segregated with disease in all affected family members. Notably, 38.1% (8/21) of the mutation carriers developed IAs, a significantly higher rate than reported in general ADPKD populations (4%–11.5%). Functional studies revealed that this mutation disrupted polycystin‐1 trafficking and impaired calcium signaling, leading to endothelial dysfunction. In vitro experiments demonstrated enhanced angiogenic potential and compromised vascular integrity in cells expressing mutant .

Conclusions

The newly identified :c.G10086T mutation represents a high‐risk genetic variant for IA development in ADPKD. Our findings provide new insights into the vascular complications of ADPKD and suggest that genotyping may help identify patients requiring intensive IA surveillance. This study supports the development of mutation‐specific screening strategies for ADPKD‐associated vascular complications.

SHORT COMMUNICATION

Background

Neuropathies associated with IgA monoclonal gammopathy are poorly understood, and the interpretation of the presence of such gammopathy in a patient with neuropathy may be challenging.

Methods

The neurological and hematological features of all patients newly diagnosed with IgA gammopathy by immunofixation in our center from January 2016 to December 2020 were retrospectively analyzed. Patients with neuropathy were identified through the medical records. The etiology was reviewed by two neurologists and classified into three groups: (i) IgA‐related neuropathies, (ii) IgA‐unrelated neuropathies with an identified alternative etiology, and (iii) neuropathies of uncertain relationship with IgA (NURIA) based on a negative extensive work‐up.

Results

Among 585 patients with IgA gammopathy, 79 had neuropathy (14%). Neuropathy was IgA‐related in 10 patients (13%): eight AL amyloidosis and two POEMS. In this group, the core features were neuropathic pain, autonomic dysfunction, fatigue or weight loss, and a lambda light chain. IgA‐unrelated neuropathies were more frequent ( = 64, 81%), encompassing mainly chemotherapy‐induced ( = 34) and diabetic ( = 15) neuropathies. Five patients (6%) were classified as NURIA: four had mild sensory‐predominant length‐dependent axonal neuropathy, and one had severe, progressive, motor‐predominant axonal neuropathy.

Conclusions

In patients with IgA gammopathy, neuropathies have a low prevalence and a wide etiological spectrum. AL amyloidosis and POEMS syndrome are rare but crucial to identify, as disease‐modifying treatments are available. Future studies should help better characterize the rare cases of neuropathy with an uncertain relationship to IgA gammopathy.